ECSP088737A - Nuevos compuestos cristalinos - Google Patents

Nuevos compuestos cristalinos

Info

Publication number
ECSP088737A
ECSP088737A EC2008008737A ECSP088737A ECSP088737A EC SP088737 A ECSP088737 A EC SP088737A EC 2008008737 A EC2008008737 A EC 2008008737A EC SP088737 A ECSP088737 A EC SP088737A EC SP088737 A ECSP088737 A EC SP088737A
Authority
EC
Ecuador
Prior art keywords
acid
naphthalene
tartaric
crystal compounds
new crystal
Prior art date
Application number
EC2008008737A
Other languages
English (en)
Inventor
Uwe Ries
Ulrike Werthmann
Sonja Sproll
Andreas Zopf
Guenther Huchler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP088737A publication Critical patent/ECSP088737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La invención se refiere a los nuevos compuestos cristalinos A de la fórmula general I (I), en la que A1, A2, A3, X, Y1, Y2 e Y3 están definidos como en la reivindicación 1, y que se presentan en forma de sus sales con ácidos, fisiológicamente tolerables, seleccionándose los ácidos a partir del grupo B constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido bencenosulfónico, ácido p?toluenosulfónico, ácido maleico, ácido succínico, ácido fumárico, ácido D?(?)?tartárico, ácido L?(+)?tartárico, ácido naftalin?2?sulfónico y ácido naftalin?1,5?disulfónico, así como a los polimorfos, a los correspondientes solvatos e hidratos.
EC2008008737A 2006-04-13 2008-09-15 Nuevos compuestos cristalinos ECSP088737A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen

Publications (1)

Publication Number Publication Date
ECSP088737A true ECSP088737A (es) 2008-10-31

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008737A ECSP088737A (es) 2006-04-13 2008-09-15 Nuevos compuestos cristalinos

Country Status (20)

Country Link
US (1) US7638625B2 (es)
EP (1) EP2010513A2 (es)
JP (1) JP2009533387A (es)
KR (1) KR20090007428A (es)
CN (1) CN101421263A (es)
AR (1) AR060442A1 (es)
AU (1) AU2007239505A1 (es)
BR (1) BRPI0710151A2 (es)
CA (1) CA2648140A1 (es)
CO (1) CO6140057A2 (es)
DE (1) DE102006017827A1 (es)
EA (1) EA200802049A1 (es)
EC (1) ECSP088737A (es)
MX (1) MX2008013158A (es)
NO (1) NO20083709L (es)
PE (1) PE20080735A1 (es)
TW (1) TW200808767A (es)
UY (1) UY30280A1 (es)
WO (1) WO2007118819A2 (es)
ZA (1) ZA200806859B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
JP2009539799A (ja) * 2006-06-08 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｇｒｐ拮抗薬
EA025358B1 (ru) * 2012-02-27 2016-12-30 Бристол-Майерс Сквибб Компани N-(5S,6S,9R)-5-АМИНО-6-(2,3-ДИФТОРФЕНИЛ)-6,7,8,9-ТЕТРАГИДРО-5H-ЦИКЛОГЕПТА[b]ПИРИДИН-9-ИЛ-4-(2-ОКСО-2,3-ДИГИДРО-1H-ИМИДАЗО[4,5-b]ПИРИДИН-1-ИЛ)ПИПЕРИДИН-1-КАРБОКСИЛАТНАЯ СОЛЬ
US12521389B2 (en) * 2019-06-14 2026-01-13 The Regents Of The University Of California Therapeutic approach to lung disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712023A (pt) 1996-09-10 1999-08-31 Thomae Gmbh Dr K Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
TW200808767A (en) 2008-02-16
NO20083709L (no) 2008-10-31
PE20080735A1 (es) 2008-07-25
BRPI0710151A2 (pt) 2011-08-02
DE102006017827A1 (de) 2007-10-18
CO6140057A2 (es) 2010-03-19
US20080086003A1 (en) 2008-04-10
WO2007118819A2 (de) 2007-10-25
ZA200806859B (en) 2009-08-26
MX2008013158A (es) 2008-10-22
AU2007239505A1 (en) 2007-10-25
WO2007118819A3 (de) 2008-05-29
CN101421263A (zh) 2009-04-29
US7638625B2 (en) 2009-12-29
KR20090007428A (ko) 2009-01-16
UY30280A1 (es) 2007-11-30
CA2648140A1 (en) 2007-10-25
AR060442A1 (es) 2008-06-18
EA200802049A1 (ru) 2009-04-28
EP2010513A2 (de) 2009-01-07
JP2009533387A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
DOP2012000149A (es) Compuestos triciclicos novedosos
CO6351724A2 (es) Inhibidores de cmet
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CL2010001588A1 (es) Proceso para preparar nodulos que comprenden al polimorfo i del inhibidor de protrombina metanosulfonato de etexilato de dabigatran; proceso para preparar una suspension que comprende metanosulfonato de etexilato de dabigatran utilizada en la preparacion de los nodulos.
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
EA201200652A1 (ru) Способ получения кальцобутрола
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA201100517A1 (ru) Способ получения дабигатрана и его промежуточные соединения
UY32077A (es) Inhibidores de quinasa tipo polo
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
PE20100051A1 (es) Nuevo procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-oa y aplicacion en la sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CL2010001639A1 (es) Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina.
ECSP088737A (es) Nuevos compuestos cristalinos
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
UY31714A (es) Preparación selectiva de pirimidinas sustituidas
CL2012000159A1 (es) Procedimiento para la preparacion estereoselectiva de compuestos (trans)- y (cis)-9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, y los compuestos intermediarios considerados.
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EP2439202A4 (en) COMPOUNDS FOR INHIBITING THE TYPE 1 11 BETA HYDROXYSTEROID DEHYDROGENASE
CL2010000254A1 (es) Procedimiento de sintesis de ivabradina por formacion de una imina; y los compuestos intermediarios considerados en el procedimiento.
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina